Locations:
June 18, 2019/Neurosciences

Identifying Risks Factors Associated With Extended Length of Stay in Posterior Segmental Instrumented Fusion for Adolescent Idiopathic Scoliosis

Effective pain relief and major postoperative complications correlate with length of stay, study finds

Goodwin, MD

The use of epidural analgesia (EA) may be a protective factor against extended length of stay (LLOS) in patients undergoing posterior segmental instrumented fusion (PSIF) for adolescent idiopathic scoliosis (AIS).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A retrospective cohort study, recently published in the journal Spine Deformity, analyzed a variety of demographic and surgical factors in order to identify independent risk factors associated with increased LOS. The two factors most strongly associated with LLOS were major postoperative complications and the use of EAs for pain management. Other factors with statistically significant correlations were female sex, ≥9 ±2 levels of fusion, amount of operative blood loss, major postoperative complications, lack of EA and higher thoracic kyphosis.

“Length of stay is important in an era of value-based care; however, studies such as this one are concerned with more than reimbursement,” states Ryan Goodwin, MD, Director of Cleveland Clinic’s Center for Pediatric and Adolescent Orthopaedics. “The modifiable risk factors we identified, such as effective pain relief and major postoperative complications, relate to patient safety and well-being and overall quality of care.”

Identifying risks factors associated with extended length of stay

The study involved retrospective analysis of data from pediatric scoliosis patients (n = 407) undergoing surgical correction from January 1, 2009 through December 31, 2017. Researchers defined a short length of stay (SLOS) as fewer than four days, and a LLOS as four or more days.

Of the patients included in this single-institution study, 232 had SLOS, with a mean stay of 3 ±0.5 days. The remaining 175 patients had LLOS, with a mean stay of 6 ±2 days. Researchers looked at factors related to a patient’s demographics, comorbidities and preoperative measurements of scoliosis curve, as well as factors related to the surgery itself and any complications.

Advertisement

Among the demographic characteristics, only female sex had statistically significant associations with LLOS. Higher thoracic kyphosis was the only preoperative radiographic measurement to correlate with LLOS. Comorbidities had no statistically significant impact on LOS.

In terms of surgery-related characteristics and postoperative complications, which might be considered somewhat modifiable risk factors, operative time and the number of osteotomies had no significant impact on LOS. Patients in whom 7 ±2 levels were fused had SLOS compared to patients who had 9 ±2 levels fused.

Opportunity to make meaningful improvements in quality of care

In patients with major postoperative complications, such as the development of motor weakness, the need for transfusion, infection or reoperation, the risk of LLOS increased 11-fold. Patients without EA for pain control, a modifiable factor, had a three-fold increased risk of LLOS. Comorbidities, preoperative curve Cobb angle and number of osteotomies did not have a statistically significant impact on LOS.

Dr. Goodwin notes, “To our knowledge, this is the largest single-institution study, looking at the most comprehensive list of potential risk factors that might impact length of stay in this patient population. One day in a U.S. hospital can cost up to $4,000. Lowering these costs by reducing the number of in-hospital recovery days is good for everyone involved—patients, providers and payers.”

Advertisement

Related Articles

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

headshots of Drs. Lilly and Barron

Early Mobilization in Neuro Intensive Care (Podcast)

Therapists and physicians collaborate to get medically stable patients moving

23-NEU-3627359-CQD-Hero-650×450

6 Things to Know About the New Home of Our Neurological Institute

Designed for digitization, distance health, discovery and more

illustration of a bright clinical room with clinicians inside

Inside Our Neurological Institute’s Next-Generation Advanced Therapeutics Space

Combining customized care, research capabilities and flexibility for the future

stylized illustration of human brain made up of cogs and wheels
October 9, 2026/Neurosciences/Brain Health

How Alzheimer’s Disease Studies Need to Evolve in the Targeted Therapy Era

Leading investigators outline a new roadmap for clinical trials and observational research

Older man tending to houseplants

TEMPO-2 Trial Shows Promise for Tavapadon in Newly Diagnosed Parkinson’s Disease

The selective D1/D5 dopamine agonist provides symptom relief and improves daily function.

illustration of human brain with swirls of activity inside it
September 23, 2026/Neurosciences/Brain Health

Cleveland ADRC Renewal Boosts Research Into Alzheimer’s Progression

5-year funding award supports cohort expansion and deep phenotyping of AD and related dementias

young man meditating on a sofa
September 21, 2026/Neurosciences/Epilepsy

Lifestyle Interventions Show Promise as Adjunctive Epilepsy Management

Highest response rates seen with stress-lowering techniques like yoga, meditation and mindfulness

Ad